Trials / Not Yet Recruiting
Not Yet RecruitingNCT07205796
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
A Phase 2, Randomized, Multicenter, Active-controlled, Double-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a 2-dose Regimen of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 79 Years Old
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 50 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 79 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HZ Vaccine (IN001) | Formulation for injection |
| BIOLOGICAL | Shingrix | Sterile suspension for injection |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
- First posted
- 2025-10-03
- Last updated
- 2025-10-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07205796. Inclusion in this directory is not an endorsement.